Conclusion of a non-exclusive rebate agreement under Section 130a(8) SGB V for the active substance mesalazine (excluding Dafo TMR), ATC A07EC02, for the period 01/06/2026 - 31/05/2028 (plus option to extend once by 12 months)

Summary

The tender concerns the conclusion of a non-exclusive rebate agreement for medicines containing mesalazine for the period 01/06/2026 to 31/05/2028, with an option to extend once by 12 months. It is an open accession model: interested pharmaceutical companies may join the agreement if they submit the required documents on time by email. The bidder must complete the tender and contract documents and should check the tender documents for the exact qualification and compliance requirements.